DSM and Crucell have launched Percivia LLC, a joint venture focused on the development of "biobetter" proteins and monoclonal antibodies using their PER.C6 technology. The company, which will be based in Cambridge, MA, will also license the PER.C6 human cell line for production of third party monoclonal antibodies and other proteins.
Crucell
Wednesday, 29 September 2010
DSM and Crucell launch newco
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment